Analgesic efficacy and safety of non-prescription doses of naproxen sodium in the management of moderate osteoarthritis of the knee or hip

被引:6
|
作者
Couto, Alisha [1 ]
Troullos, Emanuel [1 ]
Moon, Jennifer [1 ,2 ]
Paredes-Diaz, Alberto [1 ]
An, Robert [1 ]
机构
[1] Bayer Healthcare LLC, 100 Bayer Blvd, Whippany, NJ 07981 USA
[2] Rutgers State Univ, Ernest Mario Sch Pharm, Piscataway, NJ USA
关键词
Naproxen sodium; osteoarthritis; older patients; over-the-counter; pain relief; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DOUBLE-BLIND; SYSTEMATIC ANALYSIS; GLOBAL BURDEN; PLACEBO; RECOMMENDATIONS; IBUPROFEN; DISEASE; TRIALS; ACETAMINOPHEN;
D O I
10.1080/03007995.2018.1437029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Current osteoarthritis therapies aim to alleviate pain and maintain joint function. Non-prescription oral non-steroidal anti-inflammatory drugs are frequently used alone for pain relief in osteoarthritis. This post-hoc pooled analysis evaluated the analgesic efficacy and safety of two non-prescription doses of naproxen sodium for short-term use in patients with osteoarthritis of the knee or hip. A separate sub-group analysis of older patients who were administered a lower dose of naproxen sodium was performed. Methods: In four multi-center, multi-dose, randomized, parallel, double-blind, placebo-controlled studies, oral naproxen sodium (age-based dosing regimen: <65 years, 660 mg/day; >= 65 years, 440 mg/day) or placebo was administered over 7 days. Data at baseline and after 7 days in 818 patients who received naproxen sodium or placebo (n = 409 in each group) was pooled and analyzed. Five-point rating scales were used to assess knee or hip joint pain, stiffness after rest, day and night pain, and patient and investigator assessment of treatment, while function was evaluated using a timed 50-foot walk test. Results: Compared with placebo, there were significant improvements in pain and physical function with naproxen sodium (p < .05), and treatment was rated "good" to "excellent" significantly more often (p < .001) by investigators and patients. Efficacy results were similar among younger and older patients. There were no significant differences in adverse events between groups, regardless of age. Conclusions: For the acute management of underlying pain in patients with moderate osteoarthritis of the hip or knee, non-prescription naproxen sodium is effective and well tolerated in patients of all ages.
引用
收藏
页码:1747 / 1753
页数:7
相关论文
共 50 条
  • [21] Efficacy, Safety, and Tolerability of the Cyclooxygenase-Inhibiting Nitric Oxide Donator Naproxcinod in Treating Osteoarthritis of the Hip or Knee
    Karlsson, Jon
    Pivodic, Aldina
    Aguirre, Diana
    Schnitzer, Thomas J.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (06) : 1290 - 1297
  • [22] DIGITAL SELF-MANAGEMENT, ANALGESIC USE AND PATIENT-REPORTED OUTCOMES IN KNEE OR HIP OSTEOARTHRITIS
    Kiadaliri, A.
    Lohmander, S.
    Dahlberg, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1829 - 1830
  • [23] Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee
    Robert M. Levy
    Alexander Khokhlov
    Sergey Kopenkin
    Boris Bart
    Tatiana Ermolova
    Raiasa Kantemirova
    Vadim Mazurov
    Marjorie Bell
    Paul Caldron
    Lakshmi Pillai
    Bruce P. Burnett
    Advances in Therapy, 2010, 27 : 731 - 742
  • [24] Australian GP management of osteoarthritis following the release of the RACGP guideline for the non-surgical management of hip and knee osteoarthritis
    Basedow M.
    Williams H.
    Shanahan E.M.
    Runciman W.B.
    Esterman A.
    BMC Research Notes, 8 (1)
  • [25] Efficacy and Safety of Anti-Nerve Growth Factor Antibody Therapy for Hip and Knee Osteoarthritis: A Meta-analysis
    Gao, Yijie
    Hu, Zhengxu
    Huang, Yi
    Liu, Weijian
    Ren, Changle
    ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE, 2022, 10 (04)
  • [26] Safety and Efficacy of Hybrid Cooperative Complexes of Sodium Hyaluronate and Sodium Chondroitin for the Treatment of Patients with Symptomatic Knee Osteoarthritis
    Cristiano Sconza
    Dario Romano
    Dalila Scaturro
    Giulia Letizia Mauro
    Giulia Leonardi
    Angelo Alito
    Stefano Respizzi
    Elizaveta Kon
    Berardo Di Matteo
    Rheumatology and Therapy, 2024, 11 : 381 - 395
  • [27] Safety and Efficacy of Hybrid Cooperative Complexes of Sodium Hyaluronate and Sodium Chondroitin for the Treatment of Patients with Symptomatic Knee Osteoarthritis
    Sconza, Cristiano
    Romano, Dario
    Scaturro, Dalila
    Mauro, Giulia Letizia
    Leonardi, Giulia
    Alito, Angelo
    Respizzi, Stefano
    Kon, Elizaveta
    Di Matteo, Berardo
    RHEUMATOLOGY AND THERAPY, 2024, 11 (02) : 381 - 395
  • [28] Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials
    Fan, Zheng-rui
    Ma, Jian-xiong
    Wang, Ying
    Chen, Heng-ting
    Lang, Shuang
    Ma, Xin-long
    CLINICAL RHEUMATOLOGY, 2021, 40 (06) : 2155 - 2165
  • [29] UPDATE OF THE EULAR RECOMMENDATIONS FOR THE NON-PHARMACOLOGICAL CORE MANAGEMENT OF HIP AND KNEE OSTEOARTHRITIS
    Moseng, T.
    Vlieland, T. P. M. Vliet
    Battista, S.
    Beckwee, D.
    Boyadzhieva, V.
    Conaghan, P. G.
    Costa, D.
    Doherty, M.
    Finney, A.
    Georgiev, T.
    Gobbo Montoya, M.
    Kennedy, N.
    Kjeken, I.
    Kroon, F.
    Lohmander, S.
    Lund, H.
    Mallen, C.
    Pavelka, K.
    Pitsillidou, I.
    Rayman, M.
    Tveter, A. T.
    Vriezekolk, J. E.
    Wiek, D.
    Zanoli, G.
    Osteras, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 52 - 52
  • [30] Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain
    Schnitzer, Thomas J.
    Ekman, Evan F.
    Spierings, Egilius L. H.
    Greenberg, H. Scott
    Smith, Michael D.
    Brown, Mark T.
    West, Christine R.
    Verburg, Kenneth M.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (06) : 1202 - 1211